Clinical Trial Update: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 adaptive platform trial in COVID-19 and emerging infectious diseases; trial terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Emerging Infectious Disease

Snippet

Sponsor: Oslo University Hospital | Conditions: COVID-19, Emerging Infectious Disease | Phase 2, Phase 3 | Status: TERMINATED